OXUR
vs
DAX Index

Over the past 5 years, OXUR has underperformed DAX Index, delivering a return of -100% compared to the DAX Index's 49% growth.

Stocks Performance
OXUR vs DAX Index

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Performance Gap
OXUR vs DAX Index

Performance Comparison
OXUR vs DAX Index

1 Month 3 Months 6 Months 1 Year 5 Years 10 Years 20 Years
OXUR
Oxurion NV
-14%
-32%
-76%
-96%
-100%
-100%
-100%
DAX Index
Market Index
0%
4%
10%
19%
49%
104%
364%

Oxurion NV
Glance View

Market Cap
616.8k EUR
Industry
Biotechnology

Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.

OXUR Intrinsic Value
0.38 EUR
Undervaluation 37%
Intrinsic Value
Price

See Also

Back to Top